Guanine nucleotide-binding protein-like 3 (GNL3)

Guanine nucleotide-binding protein-like 3 (GNL3), commonly known as nucleostemin, is a nucleolar GTP-binding protein primarily expressed in stem cells and various cancer types (UniProt Q9BVP2). It plays a critical role in regulating cell cycle progression, ribosome biogenesis, and the maintenance of genomic stability by interacting with the p53-MDM2 pathway and DNA replication machinery (PubMed: 12464630, 20703089). GNL3 functions as a molecular switch that shuttles between the nucleolus and nucleoplasm, where it stabilizes MDM2 and prevents the activation of p53, thereby promoting cell proliferation and survival (PubMed: 12464630). In many malignancies, including prostate, liver, and lung cancers, GNL3 overexpression is associated with poor prognosis, tumor progression, and resistance to therapies (PubMed: 37345060, 30872934). Although no direct GNL3 inhibitors are currently approved, it is considered a promising therapeutic target for anti-cancer drug development due to its central role in maintaining the proliferative capacity of malignant cells (PubMed: 20703089). However, its essential role in normal stem cell maintenance and early embryonic development poses a significant challenge for drug development, as loss of GNL3 leads to early embryonic lethality (PubMed: 12464630, 22689656).

Other names

NucleosteminNSE2-induced gene 3 proteinE2IG3Novel nucleolar protein 47NNP47Nucleolar GTP-binding protein 3Nug1MGC800C77032

Modulation of protein expression, interference with nucleolar-nucleoplasmic shuttling, and regulation of the p53-MDM2 feedback loop to induce cell cycle arrest or apoptosis.